Banner Image
Mobile banner image

Pfizer Oncology
Development

Overview - by Cancer

Geo Regions

View studies/programs by

Cancer Type Phase
Cancer types
Phases
Study status

Breast Cancer

Presentation CDK2 Inhibitor + CDK4 Inhibitor

CDK2 Inhibitor + CDK4 Inhibitor

PF-07104091
PF-07220060
Go to page CDK2 Inhibitor + CDK4 Inhibitor
Presentation CDK2 Inhibitor

CDK2 Inhibitor

PF-07104091
Go to page CDK2 Inhibitor
image representing CDK4 Inhibitor

CDK4 Inhibitor

PF-07220060
Go to page CDK4 Inhibitor
Presentation Vepdegestrant (ARV-471)* + CDK4 Inhibitor

Vepdegestrant (ARV-471)* + CDK4 Inhibitor

PROTAC® Estrogen Receptor Degrader
PF-07220060
Go to page Vepdegestrant (ARV-471)* + CDK4 Inhibitor
Presentation KAT6 Inhibitor + CDK4 Inhibitor

KAT6 Inhibitor + CDK4 Inhibitor

PF-07248144
PF-07220060
Go to page KAT6 Inhibitor + CDK4 Inhibitor
rotating image for Disitamab vedotin

Disitamab vedotin

HER2-directed Antibody Drug Conjugate
Go to page Disitamab vedotin
orange rotating molecule

Felmetatug vedotin (B7-H4-directed Antibody Drug Conjugate)

PF-08046048, SGN-B7H4V
Go to page Felmetatug vedotin (B7-H4-directed Antibody Drug Conjugate)
Presentation KAT6 Inhibitor

KAT6 Inhibitor

PF-07248144
Go to page KAT6 Inhibitor
Image representing palbociclib

Palbociclib

CDK 4/6 Inhibitor
Go to page Palbociclib
Presentation Vepdegestrant (ARV-471)* + Palbociclib

Vepdegestrant (ARV-471)* + Palbociclib

PROTAC® Estrogen Receptor Degrader
CDK 4/6 Inhibitor
Go to page Vepdegestrant (ARV-471)* + Palbociclib
rotating image of Tucatinib

Tucatinib

HER2 Tyrosine Kinase inhibitor
Go to page Tucatinib
Presentation Vepdegestrant (ARV-471)*

Vepdegestrant (ARV-471)*

PROTAC® Estrogen Receptor Degrader
Go to page Vepdegestrant (ARV-471)*

Gastrointestinal Cancer

Presentation Encorafenib + Binimetinib

Encorafenib + Binimetinib

BRAF Inhibitor
MEK Inhibitor
Go to page Encorafenib + Binimetinib
rotating image for Disitamab vedotin

Disitamab vedotin

HER2-directed Antibody Drug Conjugate
Go to page Disitamab vedotin
Presentation Encorafenib

Encorafenib

BRAF Inhibitor
Go to page Encorafenib
rotating image of Tucatinib

Tucatinib

HER2 Tyrosine Kinase inhibitor
Go to page Tucatinib

Genitourinary Cancer

rotating image for Disitamab vedotin

Disitamab vedotin

HER2-directed Antibody Drug Conjugate
Go to page Disitamab vedotin
rotating image for Enfortumab vedotin

Enfortumab vedotin

Nectin-4-directed Antibody Drug Conjugate
Go to page Enfortumab vedotin
Presentation Mevrometostat (EZH2 Inhibitor) + Enzalutamide

Mevrometostat (EZH2 Inhibitor) + Enzalutamide

PF-06821497
Androgen Receptor Inhibitor
Go to page Mevrometostat (EZH2 Inhibitor) + Enzalutamide
Presentation Mevrometostat

Mevrometostat

EZH2 Inhibitor

PF-06821497
Go to page Mevrometostat
Presentation Sasanlimab

Sasanlimab

Anti-PD-1
Go to page Sasanlimab
Presentation Talazoparib

Talazoparib

PARP Inhibitor
Go to page Talazoparib

Hematological Malignancies

rotating image for Brentuximab vedotin

Brentuximab vedotin

CD30-directed Antibody Drug Conjugate
Go to page Brentuximab vedotin
rotating gif of SGN-35T

CD30-directed Antibody-Tripeptide MMAE Conjugate

PF-08046045, SGN-35T
Go to page CD30-directed Antibody-Tripeptide MMAE Conjugate
Presentation Elranatamab

Elranatamab

BCMA-CD3 Bispecific Antibody
Go to page Elranatamab
image representing maplirpacept

Maplirpacept

SIRPα-IgG4 Fusion Protein

TTI-622/PF-07901801
Go to page Maplirpacept
rotating gif for Non-Fucosylated CD70-directed Antibody

Non-Fucosylated CD70-directed Antibody

PF-08046040, SEA-CD70
Go to page Non-Fucosylated CD70-directed Antibody

Melanoma

Presentation Encorafenib + Binimetinib

Encorafenib + Binimetinib

BRAF Inhibitor
MEK Inhibitor
Go to page Encorafenib + Binimetinib
rotating image for CD228-directed Antibody-Anticalin® Bispecific Protein

CD228-directed Antibody-Anticalin® Bispecific Protein

PF-08046049, SGN-BB228 
Go to page CD228-directed Antibody-Anticalin® Bispecific Protein
Presentation Encorafenib

Encorafenib

BRAF Inhibitor
Go to page Encorafenib

Other or Multiple Cancer Types

Presentation BRAF Dimer Inhibitor V600 and BRAF Class 2/3

BRAF Dimer Inhibitor V600 and BRAF Class 2/3

PF-07799933, ARRY-440
Go to page BRAF Dimer Inhibitor V600 and BRAF Class 2/3
rotating image for CD228-directed Antibody-Anticalin® Bispecific Protein

CD228-directed Antibody-Anticalin® Bispecific Protein

PF-08046049, SGN-BB228 
Go to page CD228-directed Antibody-Anticalin® Bispecific Protein
rotating image for Disitamab vedotin

Disitamab vedotin

HER2-directed Antibody Drug Conjugate
Go to page Disitamab vedotin
rotating image for Enfortumab vedotin

Enfortumab vedotin

Nectin-4-directed Antibody Drug Conjugate
Go to page Enfortumab vedotin
orange rotating molecule

Felmetatug vedotin (B7-H4-directed Antibody Drug Conjugate)

PF-08046048, SGN-B7H4V
Go to page Felmetatug vedotin (B7-H4-directed Antibody Drug Conjugate)
Presentation Integrin alpha-V/beta-8 Antagonist

Integrin alpha-V/beta-8 Antagonist

PF-06940434 
Go to page Integrin alpha-V/beta-8 Antagonist
Presentation MEK Brain Penetrant Inhibitor

MEK Brain Penetrant Inhibitor

PF-07799544, ARRY-134
Go to page MEK Brain Penetrant Inhibitor
Presentation Mevrometostat

Mevrometostat

EZH2 Inhibitor

PF-06821497
Go to page Mevrometostat
Presentation Mevrometostat (EZH2 Inhibitor) + Enzalutamide

Mevrometostat (EZH2 Inhibitor) + Enzalutamide

PF-06821497
Androgen Receptor Inhibitor
Go to page Mevrometostat (EZH2 Inhibitor) + Enzalutamide
Presentation PF-07820435

PF-07820435

STING Agonist
Go to page PF-07820435
Presentation PF-08046050, SGN-CEACAM5C

PF-08046050, SGN-CEACAM5C

CEACAM5-directed Antibody Drug Conjugate
Go to page PF-08046050, SGN-CEACAM5C
Presentation PF-08046053, SGN-EGFRd2

PF-08046053, SGN-EGFRd2

Bispecific Gamma Delta-T-Cell Engager Directed to EGFR
Go to page PF-08046053, SGN-EGFRd2
rotating gif of PF-08046054, SGN-PDL1V

PF-08046054, SGN-PDL1V

PD-L1-directed Antibody Drug Conjugate
Go to page PF-08046054, SGN-PDL1V
green molecule rotates

Sigvotatug vedotin

Integrin beta-6 directed Antibody Drug Conjugate
Go to page Sigvotatug vedotin
rotating image of Tisotumab vedotin

Tisotumab vedotin

TF-directed Antibody Drug Conjugate
Go to page Tisotumab vedotin
rotating image of Tucatinib

Tucatinib

HER2 Tyrosine Kinase inhibitor
Go to page Tucatinib

Thoracic Cancer

rotating image for Brentuximab vedotin

Brentuximab vedotin

CD30-directed Antibody Drug Conjugate
Go to page Brentuximab vedotin
Presentation Sasanlimab

Sasanlimab

Anti-PD-1
Go to page Sasanlimab
green molecule rotates

Sigvotatug vedotin

Integrin beta-6 directed Antibody Drug Conjugate
Go to page Sigvotatug vedotin

Efficacy and safety of these products, for the uses identified within, are currently under investigation. Regulatory approval of any of these products or uses is dependent on the completion of the study programs and review by regulatory authorities. The clinical trial information is available at www.clinicaltrials.gov. This information is current as of January 30, 2024.

Anticalin® is a registered US trademark of Pieris Pharmaceuticals Gmbh.